Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q4 FY2022 Earnings Presentation
22 slides from Glenmark Pharmaceuticals's earnings presentation, May 27, 2022
Slide 1: Investors Presentation Q4 FY 21-22 & FY 21-22
Presentation Heading or Sub Heading INVESTORS PRESENTATION Q4 FY 21-22 & FY 21-22 27th May 2022
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Glenmark Pharmaceuticals Ltd. The information, statements and analysis made in this presentation describing Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. These statements are based on current expec
Slide 3: Corporate Overview
Corporate Overview Glenmark operates its businesses through three GPL is primarily focused on building a separate entities Glenmark global Generics, Specialty and OTC Pharmaceuticals business in the therapy areas of Ltd. (GPL) Dermatology, Respiratory and Oncology. www.glenmarkpharma.com Glenmark GL
Slide 4: Q4 FY2022 Snapshot
Q4 FY2022 Snapshot Revenues from operations up 5.6% YoY to Rs. 30,191 Mn Adjusted EBITDA2 of Rs. 5,022 Mn with Margin of 16.6% Adjusted PAT3,4of Rs. 2,939 Mn; growth of 25.7% ➢ Consolidated sales of Rs. 30,191 Mn ; 5.6% increase YoY “We delivered consistent performance throughout the year and achiev
Slide 5: FY 2022 Snapshot
FY 2022 Snapshot Revenues from operations up 12.4% YoY to Rs. 123,049 Mn Adjusted EBITDA2 of Rs. 23,591 Mn with Margin of 19.2% PAT of Rs. 9,936 Mn; growth of 2.4% ➢ Consolidated sales of Rs. 123,049 Mn ; 12.4% increase YoY • RoW1 business grew by 38.4% YoY • India Formulation business recorded grow
Slide 6: Glenmark delivered on the objectives set for FY22
Glenmark delivered on the objectives set for FY22 What we said…….. ….What we delivered Revenue growth of 12.4% 1• Revenue growth of 10-15% during the year during the year EBITDA1 margin of 18.9% as 2• Sustain EBITDA margin performance at similar levels of FY21 compared to 19.0% in FY21 • Reduce debt
Slide 7: Other Key Highlights for the year
Other Key Highlights for the year Listed wholly owned API subsidiary, Glenmark Lifesciences Ltd on the Indian exchanges Selected for the PLI scheme aimed at Listed in prestigious Dow Jones Sustainability improving India’s manufacturing capabilities Emerging Markets Index for the fourth and enhancing
Slide 8: Consolidated Revenues from Operations
Consolidated Revenues from Operations Fourth quarter ended March 31 ‘22 Year ending Mar 31 ‘22 Rs Mn FY 2021-22 FY 2020-21 YoY Growth (%) FY 2021-22 FY 2020-21 YoY Growth (%) India 8,847 8,238 7.4% 40,855 35,365 15.5% North America 7,378 8,012 -7.9% 30,366 30,764 -1.3% Europe 4,968 4,223 17.6% 15,21
Slide 9: Revenue distribution by key geographies
Revenue distribution by key geographies 1% 1% 12% 11% 29% 29% 15% 16% Q4FY21 Q4FY22 16% 18% 28% 24% India Rest of the World (ROW) API North America Europe Other Revenue 9
Slide 10: P&L Highlights - Consolidated
P&L Highlights - Consolidated Rs Mn 4Q FY22 4Q FY21 %YoY FY22 FY21 %YoY Revenues from Operations 30,191 28,599 5.6% 123,409 109,439 12.4% EBITDA 4,634 5,234 (11.5)% 23,203 20,844 11.3% EBITDA margin (%) 15.3% 18.3% 18.9% 19.0% Other Income (exp) 1,072 85 1,667 502 Exceptional1 gain (loss) (825) 0 (2
Slide 11: Key Balance Sheet Items
Key Balance Sheet Items Rs Mn Mar ’22 Mar ‘21 Trade Receivables 31,011 25,721 Inventory 24,998 22,768 Gross Debt 36,703 46,874 Cash & Equivalents 14,105 11,381 Net Debt 22,598 35,490 Equity 90,866 70,646 11
Slide 12: India formulations
India formulations 29% Non-COVID base portfolio Rank 2nd in Dermatology, grew 15.5 % as compared Launched 31 new products 4th in Respiratory and 6th in to the non-COVID IPM during the year Cardio Vascular 1 growth of 10.6% 2 Key Highlights Revenue (INR Mn) • Sales of Rs. 8,847 Mn recording growth of
Slide 13: North America
North America 24% Clindamycin Phosphate 19 ANDAs filed with USFDA Launched 10 new products Foam, Theophylline ER tab in FY22 during the year approved Key Highlights Revenue (INR Mn) • Sales of Rs. 7,378 Mn (USD 98 Mn) as compared to Rs. 8,012 Mn (USD 110 Mn) in Q4 FY21 recording decline of (7.9)% Yo
Slide 14: Europe
Europe 16% Ryaltris™ marketing Launched Ryaltris™ in UK, Recorded sales in excess of approval received in all EU Czech, Poland and Italy USD 200 Mn for the first markets during the year time Key Highlights Revenue (INR Mn) • Recorded annual sales of USD 205 Mn for the first time in the region 14.6%
Slide 15: RoW (Asia, MEA, RCIS and LATAM)
RoW (Asia, MEA, RCIS and LATAM) 18% Secondary sales in Asia Secondary sales in Russia Primary sales in MEA grew 53% YoY during the grew by 31% YoY during recorded growth of 13% quarter the quarter YoY during the quarter Key Highlights Revenue (INR Mn) • Sales of Rs. 5,479 Mn as against Rs. 4,641 Mn
Slide 16: Glenmark Life Sciences (GLS)
11% Glenmark Life Sciences (GLS) Total revenue (incl. Captive Consolidated EBITDA of Rs. Regulated markets sales) of Rs. 5,140 Mn in 1,473 Mn with margin of witnessed a healthy growth Q4 FY22; grew 10% YoY 28.7% for the quarter of 21.4% YoY in FY22 Key Highlights External Revenue (INR Mn) • External
Slide 17: Respiratory Strategy – Creating Global Scale
Respiratory Strategy – Creating Global Scale • Ryaltris™ (olopatadine hydrochloride and mometasone furoate) Nasal Spray, received FDA approval in the United States for the treatment of symptoms of Seasonal Allergic Rhinitis in adults and pediatric patients 12 years of age and older. • Marketing appr
Slide 18: R&D update - Specialty
R&D update - Specialty • Successful Phase 1 results for GBR 310 that suggest similarity in pharmacokinetic, pharmacodynamic, safety and immunogenicity profiles between GBR 310, and the reference product, Omalizumab, marketed in the U.S. under GBR 310 the brand name Xolair® • Glenmark continue to loo
Slide 19: Ichnos Sciences is a Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology
Ichnos Sciences is a Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology • Global footprint: U.S. and Switzerland Fully Integrated • Fully owned by Glenmark, with plans to expand the investor base in the future Biotech • Accomplished management team with proven track reco
Slide 20: Ichnos is Advancing a Differentiated Pipeline with Potential First – and Best-in-Class Assets
Ichnos is Advancing a Differentiated Pipeline with Potential First – and Best-in-Class Assets Ichnos Oncology Pipeline - First Wave Focuses on T-Cell Ichnos Out-Licensing Assets in Autoimmune (AI) Disease Engagers and Macrophage Modulators Clinical Molecule Potential Candidate Target Preclinical Sta
Slide 21: Key Objectives for Financial Year (FY 22-23)
Key Objectives for Financial Year (FY 22-23) 1• Revenue growth of 6-8% during the year 2• Sustain EBITDA margin performance at similar levels of FY22 3• Strategic priority to enhance free cash generation for further debt reduction 4• Capex of Rs. 7-8 Bn 5• Close 1-2 out-licensing agreements in our i
Slide 22: Thank You
Thank You www.glenmarkpharma.com
Glenmark Pharmaceuticals — Q4 FY2022 Earnings Presentation on 6ix